Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1–high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part 1
- DOI
- 10.1016/j.lungcan.2026.109316
- Published
- 2026-05
- Container
- Lung Cancer
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.lungcan.2026.109316,
title = {Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1–high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part 1},
author = {Jarushka Naidoo and Solange Peters and Yotsawaj Runglodvatana and Jacky Yu-Chung Li and Chin Heng Fong and Gwo Fuang Ho and Soon Hin How and Jitlada Juengsamarn and Julie R Graham and Neyssa Marina and Thao Dang and Deepa Patel and Sasha Han and Candy Bermingham and Melissa L Johnson},
year = {2026},
journal = {Lung Cancer},
doi = {10.1016/j.lungcan.2026.109316},
url = {https://doi.org/10.1016/j.lungcan.2026.109316}
}RIS
TY - JOUR TI - Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1–high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part 1 AU - Jarushka Naidoo AU - Solange Peters AU - Yotsawaj Runglodvatana AU - Jacky Yu-Chung Li AU - Chin Heng Fong AU - Gwo Fuang Ho AU - Soon Hin How AU - Jitlada Juengsamarn AU - Julie R Graham AU - Neyssa Marina AU - Thao Dang AU - Deepa Patel AU - Sasha Han AU - Candy Bermingham AU - Melissa L Johnson PY - 2026 JO - Lung Cancer DO - 10.1016/j.lungcan.2026.109316 UR - https://doi.org/10.1016/j.lungcan.2026.109316 ER -
APA
Naidoo, J., Peters, S., Runglodvatana, Y., Li, J. Y., Fong, C. H., Ho, G. F., How, S. H., Juengsamarn, J., Graham, J. R., Marina, N., Dang, T., Patel, D., Han, S., Bermingham, C., & Johnson, M. L. (2026). Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1–high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part 1. Lung Cancer. https://doi.org/10.1016/j.lungcan.2026.109316
Source records
- crossref · retrieved 2026-09-26T13:13:06.571Z